Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Repurposing Anti-Viral Subunit and mRNA Vaccines T Cell Immunity for Intratumoral Immunotherapy against Solid Tumors
[npj Vaccines] Scientists investigated intratumoral delivery of three licensed viral vaccines— Shingrix, Gardasil-9, and Spikevax —in prevaccinated mice using the murine tumor model TC-1, which expressed HPV16 oncogenes E6 and E7.
Novel Humanized CD19-CAR-T (Now Talicabtagene Autoleucel, Tali-Celâ„¢) Cells in Relapsed/ Refractory Pediatric B-Acute Lymphoblastic leukemia- an Open-Label Single-Arm Phase-I/Ib Study
[Blood Cancer Journal] Investigators developed a novel humanized CD19-directed CAR-T approved for Phase I/Ib/II trials. Patients aged 3–25 years were enrolled with relapsed/refractory B-acute lymphoblastic leukemia and ineligible for allogeneic stem cell transplant.
HHV-6 and HHV-7 Reactivation in Allogeneic CAR-T Cell Therapy
[Trends in Biotechnology] Scientists explore human herpesviruses 6 and 7 (HHV-6 and HHV-7) reactivations in CAR-T cell therapy and discuss mitigation strategies during allogeneic CAR-T cell manufacturing.
Bridging Intensity Is Associated with Impaired Hematopoietic Recovery following BCMA CAR-T Therapy for Multiple Myeloma
[Blood Advances] In this multicenter international observational study, researchers explored the impact of bridging therapy on hematopoietic reconstitution in 158 patients with relapsed/refractory multiple myeloma treated with B-cell maturation antigen-directed CAR T-cell therapy.
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
[JAMA Oncology] In this Phase II, single-arm, nonrandomized clinical trial that included 28 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia, the complete molecular remission rate after CD19 chimeric antigen receptor (CAR) T cell therapy was 85%.
Dual Modulation of Cytotoxic and Checkpoint Receptors Tunes the Efficacy of Adoptive Delta One T Cell Therapy against Colorectal Cancer
[Nature Cancer] Investigators demonstrated the capacity of Delta One T cells to target colorectal cancer (CRC) cell lines and patient-derived specimens and organoids in vitro and to control tumor growth in an orthotopic xenograft model of CRC.
Overcoming Extracellular Vesicle-Mediated Fratricide Improves CAR T Cell Treatment against Solid Tumors
[Nature Cancer] The authors reported that solid tumors responded to CAR T cells by upregulating the secretion of small extracellular vesicles carrying tumor antigens, which were horizontally transferred to CAR T cells, leading to antigen recognition and CAR T cell fratricide.
AAV1 CFTR Preferentially Transduces Cysts and Reduces Cyst Size in a Mouse Model of ADPKD
[American Journal of Physiology - Cell Physiology] To overcome the challenges of developing a gene therapy for ADPKD, scientists focused on the surface receptors expressed in cystic epithelia.
Deciphering Enhancers of Hearing Loss Genes for Efficient and Targeted Gene Therapy of Hereditary Deafness
[Neuron] Researchers introduced an AAV-reporter-based in vivo transcriptional enhancer reconstruction workflow, enabling efficient and reliable dissection of enhancers.
Clinical Perspective: Advancing Hemophilia Treatment through Gene Therapy Approaches
[Molecular Therapy] Three primary gene therapy approaches at the forefront of clinical development are reviewed. Adeno-associated virus-based gene therapy, having secured approval in the EU, UK, and USA after promising Phase III trial results, demonstrates clear superiority over standard-of-care treatment.
Safety and Feasibility of 4-1BB Co-Stimulated CD19-Specific CAR-NK Cell Therapy in Refractory/Relapsed Large B Cell Lymphoma: A Phase 1 Trial
[Nature Cancer] Researchers generated CD19-specific CAR-NK cells with 4-1BB and CD3ζ signaling endo-domains by transduction of cord blood-derived NK cells using baboon envelope pseudotyped lentiviral vectors and demonstrated their antitumor activity in preclinical B cell lymphoma models in female mice.
AAV Vectors Trigger DNA Damage Response-Dependent Pro-Inflammatory Signaling in Human iPSC-Derived CNS Models and Mouse Brain
[Nature Communications] Scientists uncovered vector-induced innate immune mechanisms that contributed to cell death. While empty AAV capsids were well tolerated, the AAV genome triggered p53-dependent DNA damage responses across CNS cell types followed by the induction of inflammatory responses.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.
